Urist Marshall — SEC insider filings
SEC reporting owner CIK 1838139. 36 insider filings on record with FilingPulse; latest filed 2026-11-18.
Transaction summary — filings shown
Covers all 36 filings on record, filed 2021-05-11 to 2026-11-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 30 legs across 24 filings — 465,001 shares, $20,309,575 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 21.
- Largest priced transaction: sale of 23,592 shares @ $69.47 ($1,638,939) in Royalty Pharma plc, filed 2026-11-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Royalty Pharma plc (RPRX) | EVP, Research & Investments | 36 | — | 30 legs · 465,001 sh · $20,309,575 | 21 |
Insider filings — Urist Marshall
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 23,592 @ $69.47 · Sale (S): 1,408 @ $69.99 | EDGAR |
| 2026-11-06 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 5,341 @ $0 · Conversion (C): 150,000 @ $0 · Conversion (C): 15,000 (derivative) @ $0 | EDGAR |
| 2026-10-05 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 4,126 @ $57.10 | EDGAR |
| 2026-09-30 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 4,126 @ $57.88 | EDGAR |
| 2026-08-07 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 8,252 @ $0 · Gift (G): 3,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 9,099 @ $55.88 | EDGAR |
| 2026-06-25 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 9,098 @ $55.18 | EDGAR |
| 2026-05-21 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 13,684 @ $52.75 | EDGAR |
| 2026-05-15 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 13,684 @ $53.06 | EDGAR |
| 2026-05-08 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 18,197 @ $0 | EDGAR |
| 2026-02-13 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 19,970 @ $0 | EDGAR |
| 2026-02-02 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 20,000 @ $41.09 | EDGAR |
| 2026-01-26 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 20,000 @ $40.26 | EDGAR |
| 2026-01-20 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 20,000 @ $39.52 | EDGAR |
| 2026-01-13 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 20,000 @ $40.78 | EDGAR |
| 2026-01-06 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 20,000 @ $38.48 | EDGAR |
| 2025-12-29 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 20,000 @ $39.32 | EDGAR |
| 2025-12-22 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 20,000 @ $38.38 | EDGAR |
| 2025-12-17 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 20,000 @ $38.32 | EDGAR |
| 2025-12-09 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 23,334 @ $39.15 · Sale (S): 18,242 @ $39.15 | EDGAR |
| 2025-12-03 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 23,333 @ $39.93 · Sale (S): 18,242 @ $39.90 | EDGAR |
| 2025-11-07 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 4,626 @ $0 · Conversion (C): 160,000 @ $0 · Conversion (C): 16,000 (derivative) @ $0 | EDGAR |
| 2025-08-08 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 2,772 @ $0 · Gift (G): 3,000 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,356,528 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 36,484 @ $0 | EDGAR |
| 2024-08-12 | 4 | Royalty Pharma plc (RPRX) | Gift (G): 2,182 (derivative) @ $0 | EDGAR |
| 2023-02-24 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 23,333 @ $37.30 | EDGAR |
| 2023-02-17 | 4 | Royalty Pharma plc (RPRX) | Conversion (C): 70,000 @ $0 · Conversion (C): 7,000 (derivative) @ $0 | EDGAR |
| 2022-07-27 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 3,600 @ $43.05 · Sale (S): 19,734 @ $43.20 | EDGAR |
| 2022-06-24 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 23,333 @ $43.19 | EDGAR |
| 2022-05-16 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 23,333 @ $39.85 | EDGAR |
| 2022-05-11 | 4 | Royalty Pharma plc (RPRX) | Conversion (C): 70,000 @ $0 · Conversion (C): 7,000 (derivative) @ $0 | EDGAR |
| 2021-06-08 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 16,566 @ $45.13 · Sale (S): 16,568 @ $47.02 | EDGAR |
| 2021-06-04 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 14,566 @ $41.52 | EDGAR |
| 2021-05-24 | 4 | Royalty Pharma plc (RPRX) | Sale (S): 1,900 @ $41.08 · Sale (S): 100 @ $41 | EDGAR |
| 2021-05-11 | 4 | Royalty Pharma plc (RPRX) | Conversion (C): 49,700 @ $0 · Conversion (C): 4,970 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1838139 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs